close

Enter

Log in using OpenID

Anti-Obesity Drugs Market

embed
Anti-obesity Drugs are pharmacological agents that reduce or control the weight. These drugs change one of the fundamental processes of human body
Anti-Obesity Drugs Market In-Depth Analysis By
2026
Anti-obesity Drugs are pharmacological agents that reduce or control the weight. These drugs
change one of the fundamental processes of human body, weight regulation, either by changing
the absorption of calories or dipping the hunger. Appetite control is achieved by using the
agonists for appetite suppressing pathways. Various anti-obesity drugs, which are approved from
the past decade such as knoll and acomplia (romonabant) are removed, as they cause suicidal
thoughts, depression, and cardiovascular problems, due to their long-term usage.
Get Sample Copy At: https://www.coherentmarketinsights.com/insight/request-sample/2824
Global Anti-Obesity Drugs Market- Dynamics
Increasing prevalence of obesity, adoption of deskbound lifestyle, increasing geriatric population,
and chronic nature of disease is expected to augment market growth. Furthermore, faulty eating
habits and rising consumption of fast food coupled with lack exercise is driving the market
globally. In October 2018, Novo Nordisk launched new obesity treatment on world obesity day.
The company announced the availability of Saxenda in Singapore, which is a Health Sciences
Authority (HSA) approved injectable medicine that is used with low calorie meal plan and helps
the adults who are obese or who are overweight with at least one weight associated medical
problem to lose weight.
Basic activities such reducing the intake of unhealthy food and inculcating workout are not seen
to be highly effective, and the medical devices such as intragastric balloon and bariatric surgery
have complications and are highly expensive. All this shows difficulties in treatment of obesity.
These unmet needs are driving growth of global anti-obesity drugs market. For instance, in
September, 2014, the U.S. FDA’s approved a new prescription weight loss pill- Contrave for
obese adults, the new drug is the third prescription weight loss drug approved by the FDA.
Report includes chapters which deeply display the following deliverable about industry :
• Anti-Obesity Drugs Market Research Objective and Assumption
• Anti-Obesity Drugs Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Anti-Obesity Drugs Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Anti-Obesity Drugs Market, By Regions
• Anti-Obesity Drugs Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Anti-Obesity Drugs Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Anti-Obesity Drugs Market Manufacturing Cost Analysis including Key Raw Materials and Key
Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Anti-Obesity Drugs Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Global Anti-Obesity Drugs Market- Regional Dynamics
North America has witnessed significant growth in the recent past, owing to high level of
awareness among the people with obesity and the higher risks associated with the medical
condition, rise in healthcare expenditure, extensive and effective research and development
activities, involvement of government and non-government organizations in creating an
awareness and funding the research and higher number of adults with obesity in the region.
According to the World Health Organization, in 2016, over 1.9 billion adults who were aged 18
years and above were overweight and of these over 650 million were obese.
Global Anti-Obesity Drugs Market- Competitive Analysis
Manufactures are focused on development, manufacturing, and marketing of multisource and
branded pharmaceuticals. Key players in the global anti-obesity drug market are innovating new
and efficient anti-obesity drugs by adopting novel strategies to meet the demand from customers
with various types of obesity problems. For instance, in 2017, Boehringer Ingelheim GmbH and
Gubra announced collaboration and license agreement for the development of novel peptide
compounds to treat the obesity. Furthermore, in March, 2019, Merck and Co and NGM
Biopharmaceuticals developed new range of obesity management drugs.
Key players operating in the global anti-obesity drugs market include Arena Pharmaceuticals
Inc., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Orexigen Therapeutics Inc., Norgine B.V.,
Pfizer Inc., Merck Co& Inc., Takeda Pharmaceuticals Co. Ltd., Zydus Cadila, Novo Nordisk,
Zafgen, GlaxoSmithKline PLC, and Hoffmann-La Roche AG
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/anti-obesity-drugs-market-2824
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Author
Alex Huge
Alex Huge367   documents Email
Document
Category
Health and Medicine
Views
1
File Size
108 KB
Tags
anti, Anti-Obesity Drugs Market
1/--pages
Report inappropriate content